Lilly drug cuts risk of advanced breast cancer progression -study

Sept 9 (Reuters) – An experimental Eli Lilly and Codrug taken withstandard therapy reduced the risk of diseaseprogression by 46 percent versus standard therapy alone in womennot previously treated for advanced breast cancer, according tointerim data from a late stage study presented at a medicalmeeting.
The post Lilly drug cuts risk of advanced breast cancer progression -study appeared first on RocketNews | Top News Stories From Around the Globe.